Myelofibrosis
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Pankit Vachhani, MDMyelofibrosis | May 12, 2025
Experts discuss patient-centered approaches and novel therapies reshaping MF treatment in a roundtable.
Prithviraj Bose, MDMyelofibrosis | May 12, 2025
Experts explore anemia therapies, JAK inhibitors, and transplant innovations shaping the promising future of MF care.
Naseema Gangat, MBBSMyelofibrosis | May 12, 2025
Experts discuss molecular insights into MF, highlighting mutations, risk assessment, and evolving therapeutic approaches.
Prithviraj Bose, MDMyelofibrosis | May 12, 2025
Experts discuss current treatments and ongoing research in myelofibrosis, highlighting new therapies and clinical trials.
Idoroenyi Amanam, MDMyelofibrosis | May 12, 2025
Experts discuss CALR-targeting therapies, symptom assessment, and the future of myelofibrosis treatment and regulation.
Andrew MorenoMyelofibrosis | March 28, 2025
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Advertisement
Melissa BadamoMyelofibrosis | March 27, 2025
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
Andrew MorenoMyelofibrosis | March 27, 2025
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
Nichole TuckerMyelofibrosis | March 25, 2025
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Andrew MorenoPolycythemia Vera | March 25, 2025
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
Melissa BadamoMyelofibrosis | March 25, 2025
Most patients with JAK2, CALR, and MPL mutations had mutation clearance 100 days after HSCT.
Melissa BadamoMyelofibrosis | March 10, 2025
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
John Mascarenhas, MDMyelofibrosis | February 18, 2025
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
John Mascarenhas, MDMyelofibrosis | February 18, 2025
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
John Mascarenhas, MDMyelofibrosis | February 18, 2025
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Prithviraj Bose, MDMeeting News | December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Prithviraj Bose, MDMyelofibrosis | December 31, 2024
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
Advertisement
Advertisement